A Population Pharmacokinetic Model of Tocilizumab in Kidney Transplant Patients Treated for Chronic Active Antibody-Mediated Rejection: Comparison of Plasma Exposure Between Intravenous and Subcutaneous Administration Schemes [0.03%]
一项关于tocilizumab在治疗慢性活跃型抗体介导的排斥反应的肾移植患者中的群体药代动力学模型：静脉注射与皮下给药方案后的血浆暴露量比较
Capucine Arrivé,Caroline Bazzoli,Thomas Jouve et al.
Capucine Arrivé et al.
Background: Tocilizumab prevents the clinical worsening of chronic active antibody-mediated rejection (CAAMR) in kidney transplant recipients. Following a global shortage of the intravenous pharmaceutical form in 2022, pa...
Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial [0.03%]
治疗中至重度特应性皮炎成人患者的长效及安全性：一项开放式标签扩展非随机临床试验
Yan Zhao,Jing-Yi Li,Bin Yang et al.
Yan Zhao et al.
Background: Stapokibart/CM310, a humanized monoclonal antibody targeting the interleukin-4 receptor α chain, has shown promising treatment benefits in patients with moderate-to-severe atopic dermatitis in previous phase ...
Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors [0.03%]
协同前景：局部干预与CAR-T细胞治疗在实体瘤中的应用展望
Anne Holtermann,Mila Gislon,Martin Angele et al.
Anne Holtermann et al.
Chimeric antigen receptor T cell therapy has been established in the treatment of various B cell malignancies. However, translating this therapeutic effect to treat solid tumors has been challenging because of their inter-tumoral as well as...
Hannah A Blair
Hannah A Blair
Insulin icodec (AWIQLI®) is an ultra-long-acting basal insulin analogue that is being developed by Novo Nordisk for the treatment of diabetes mellitus. Administered once weekly as a subcutaneous injection, insulin icodec is designed to imp...
Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases [0.03%]
用于治疗传染病的单B细胞筛选单克隆抗体技术
John S Schardt,Neelan S Sivaneri,Peter M Tessier
John S Schardt
The screening of antigen-specific B cells has been pivotal for biotherapeutic development for over four decades. Conventional antibody discovery strategies, including hybridoma technology and single B cell screening, remain widely used base...
Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study [0.03%]
利妥昔单抗ABPC与利妥昔单抗治疗弥漫大B细胞淋巴瘤非劣效性研究结局分析
Helen W Wong,Vivian H Nguyen,Timothy Y Mok et al.
Helen W Wong et al.
Background: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the first line treatments for diffuse large B-cell lymphoma (DLBCL). Rituximab comprises most of the treatment cost ...
Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs [0.03%]
美国食品药品监督管理局批准反义寡核苷酸药物的作用机制
Angela Sang,Selena Zhuo,Adara Bochanis et al.
Angela Sang et al.
Antisense oligonucleotides (ASOs) are single stranded nucleic acids that target RNA. The US Food and Drug Administration has approved ASOs for several diseases. ASOs utilize three principal modes of action (MOA). The first MOA is initiated ...
Stem Cells and Stem Cell-Derived Factors for the Treatment of Inflammatory Bowel Disease with a Particular Focus on Perianal Fistulizing Disease: A Minireview on Future Perspectives [0.03%]
有关干细胞及其衍生因子治疗炎症性肠病（尤其是肛周瘘管型疾病）的未来展望的小综述
Amy L Lightner,Peter M Irving,Graham M Lord et al.
Amy L Lightner et al.
Inflammatory bowel disease remains a difficult disease to effectively treat, especially fistulizing Crohn's disease. Perianal fistulas in the setting of Crohn's disease remain an area of unmet need with significant morbidity in this patient...
Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab [0.03%]
贝伐珠单抗类似药BAT1806/BIIB800与原研托利珠单抗的理化和功能相似性研究
Yujie Liu,Jianhua Xie,Zhuxiang Li et al.
Yujie Liu et al.
Background and objective: Tocilizumab is an immunoglobulin G1 monoclonal antibody targeting the interleukin-6 receptor (IL-6R). BAT1806/BIIB800 (tocilizumab-bavi) has been developed as a biosimilar to the reference produc...
Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review [0.03%]
基于演员网络理论的影响生物类似药采纳的因素及障碍的系统评价
Chad Rieger,Judith A Dean,Lisa Hall et al.
Chad Rieger et al.
Background and objective: Biosimilars represent an opportunity to realise savings against the costs of innovative medicines. Despite efforts made by stakeholders, there are numerous barriers to the uptake of biosimilars. ...